Akero shareholders will receive $54 per share initially, plus $6 per share contingent on U.S. regulatory approval of its EFX drug.
Continue Reading
View Comments
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Published 1 month ago
Oct 9, 2025 at 10:39 AM
Neutral
Auto